-
Sex Differences in the Association Between Stress, Loneliness, and COVID-19 Burden among People with HIV in the US AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-02-25 Dr. Deborah L Jones; Ms. Violeta J Rodriguez; Dr. Ana S. Salazar; Ms. Emily Montgomerie; Dr. Patricia D Raccamarich; Ms. Claudia Uribe Starita; Dr. Irma T Barreto Ojeda; Dr. Laura Beauchamps; Mr. Andres Vazquez; Ms. Thais Martinez; Dr. Maria L Alcaide
Abstract Background: Little is known about the psychological implications of the COVID-19 pandemic on people with HIV (PWH). The purpose of this study was to assess the impact of COVID-19 among men and women with HIV in Miami FL, USA. We hypothesized that the burden of the COVID-19 pandemic will be higher for women , and psychological factors will increase COVID-19 burden among them. Methods: People
-
Preventive behaviors and mental-health related symptoms among immunocompromised adults during the COVID-19 pandemic: an analysis of the COVID Impact Survey AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-02-25 Dr. Jessica Yasmine Islam; Dr. Denise Christina Vidot; Mr. Amoghavarsha Havanur; Dr. Marlene Camacho-Rivera
Background: The COVID-19 pandemic has disrupted the continuity of care of U.S. adults living with chronic diseases, including immunocompromised adults. Disruption in care may be a barrier to identifying COVID-19 associated sequelae, such as mental health symptoms, among the immunocompromised. Our objectives were (1) to evaluate COVID-19-related preventive behaviors, with a focus on canceling doctor’s
-
Higher Tenofovir Concentrations in Hair Are Associated with Decreases in Viral Load and Not Self-Reported Adherence in HIV-Infected Adolescents with Second-Line Virological Treatment Failure AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-02-24 Tariro Chawana; Charles Nhachi; Kusum Nathoo; Bernard Ngara; Hideaki Okochi; Alexander Louie; Karen Kuncze; David Katzenstein; John Metcalfe; Monica Gandhi
Objective methods of measuring antiretroviral adherence are limited. We assessed the relationship between tenofovir disoproxil fumarate (TDF) hair concentrations, self-reported adherence, and virological outcomes in HIV-infected adolescents in Harare, Zimbabwe. HIV-infected adolescents on atazanavir/ritonavir-based second-line treatment for >6 months with viral load (VL) ≥1,000 copies/mL were randomized
-
Recrudescence of Natural Coccidioidomycosis During Combination Antiretroviral Therapy in a Pigtail Macaque Experimentally Infected with Simian Immunodeficiency Virus AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-02-23 Kathryn A. Guerriero; Robert D. Murnane; Thomas B. Lewis; Brieann Brown; Audrey Baldessari; Dean A. Jeffery; Carolyn M. Malinowski; Deborah H. Fuller; Megan A. O'Connor
Coccidioidomycosis is a common fungal infection in people living with HIV-1, particularly in southwest regions of the United States where the Coccidioides sp. is endemic, but rates of infection have significantly declined in the era of potent combination antiretroviral therapy (cART). Natural coccidioidomycosis also occurs in outdoor-housed macaques residing in the southwestern states that are utilized
-
Darunavir/cobicistat is associated with negative outcomes in HIV-negative patients with severe COVID-19 pneumonia AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-02-23 Dr. Jovana Milic; Mr. Alessio Novella; Dr. Marianna Meschiari; Dr. Marianna Menozzi; Dr. Antonella Santoro; Dr. Andrea Bedini; Dr. Gianluca Cuomo; Dr. Erica Franceschini; Dr. Margherita Digaetano; Dr. Federica Carli; Dr. Giacomo Ciusa; Dr. Sara Volpi; Dr. Erica Bacca; Dr. Giacomo Franceschi; Dr. Dina Yaacoub; Dr. Carlotta Rogati; Dr. Marco Tutone; Dr. Giulia Burastero; Dr. Matteo Faltoni; Dr. Vittorio
Background The aim of this study was to evaluate both positive outcomes, including reduction of respiratory support aid and duration of hospital stay, and negative ones, including mortality and a composite of invasive mechanical ventilation or death, in patients with COVID-19 pneumonia treated with or without oral darunavir/cobicistat (DRV/c, 800/150 mg/day) used in different treatment duration. Secondary
-
Human Immunodeficiency Virus Persistence in the Spleen: Opportunities for Pharmacologic Intervention AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-02-22 Aaron S. Devanathan; Angela D.M. Kashuba
The persistence of HIV in the spleen, despite combination antiretroviral therapy, is not well understood. Sustained immune dysregulation and delayed immune recovery, in addition to immune cell exhaustion, may contribute to persistence of infection in the spleen. Eliminating HIV from this secondary lymphoid organ will require a thorough understanding of antiretroviral (ARV) pharmacology in the spleen
-
Long-acting injectables come of age to change the HIV therapeutic landscape and the lives of persons with HIV AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-02-19 Dr. Kimberly Smith
n/a
-
Impact of Plasma IP-10/CXCL10 and RANTES/CCL5 Levels on Neurocognitive Function in HIV Treatment-Naive Patients AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-02-17 Vurayai Ruhanya; Graeme B. Jacobs; Shalena Naidoo; Robert H. Paul; John A. Joska; Soraya Seedat; George Nyandoro; Susan Engelbrecht; Richard H. Glashoff
Immune activation, which is accompanied by the production of proinflammatory cytokines, is a strong predictor of disease progression in HIV infection. Inflammation is critical in neuronal damage linked to HIV-associated neurocognitive disorders. We examined the relationship between plasma cytokine levels and deficits in neurocognitive function. Multiplex profiling by Luminex® technology was used to
-
Exploring the Association Between Depression and Social and Biobehavioral HIV Risk Factors Among Female Sex Workers in Nelson Mandela Bay Municipality, South Africa AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-02-17 Johannes Rossouw; Sheree Schwartz; Amrita Rao; Mfezi Mcingana; Katherine Young; Harry Hausler; Stefan Baral
The aim of this study was to estimate the prevalence of depression among female sex workers (FSW) in an urban coastal city in South Africa, and to explore the relationship between depression and HIV-related social and biobehavioral determinants. A cross-sectional respondent-driven sampling study was conducted with FSW (n = 410), including a sociobehavioral questionnaire, PHQ-9 (Patient Health Questionnaire-9)
-
Determinants of HIV-1 Late Presentation in a Cohort of Portuguese HIV-1 Patients AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-02-16 Ana Cláudia Miranda; Mafalda Miranda; Marta Pingarilho; Victor Pimentel; João Torres; Susana Peres; Teresa Baptista Alberto; Perpetua Gomes; Ana Abecasis; Kamal Mansinho
Undiagnosed HIV-1 patients still account for 25% of worldwide HIV patients. Studying late presenters (LPs) for HIV care may help to identify characteristics of such patients. The present study aims to identify factors associated with late presentation and late presentation with advanced disease based on a population of patients followed in a Portuguese hospital between 1984 and 2017. Sociodemographic
-
Evaluation of Antiretroviral Drug Concentrations in Minimally Invasive Specimens for Potential Development of Point-of-Care Drug Assays AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-02-16 Richard E. Haaland; Amy Martin; Melkam Mengesha; Chuong Dinh; Jeffrey Fountain; L. Davis Lupo; LaShonda Hall; Christopher Conway-Washington; Colleen F. Kelley
Point-of-care (POC) tests for antiretroviral drugs (ARVs) could help improve individual adherence. This study sought to define the utility of urine, blood, and buccal swabs as minimally invasive specimens amenable to development of POC tests for ARVs. Urine, dried blood spots (DBS) and buccal swabs were collected from 35 HIV-negative men between 2 and 96 h after a single dose of tenofovir (TFV) al
-
Participant Perspectives and Experiences Entering an Intensively Monitored Antiretroviral Pause: Results from the AIDS Clinical Trials Group A5345 Biomarker Study AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-02-16 Karen L. Diepstra; Liz Barr; David Palm; Evelyn Hogg; Katie R. Mollan; Laney Henley; Angela M. Stover; Jane M. Simoni; Jeremy Sugarman; Brandon Brown; John A. Sauceda; Steven Deeks; Lawrence Fox; Rajesh T. Gandhi; Davey Smith; Jonathan Z. Li; Karine Dubé
The AIDS Clinical Trials Group (ACTG) A5345 study included an intensively monitored antiretroviral pause (IMAP), during which a cohort of participants temporarily stopped antiretroviral treatment during chronic HIV infection. We surveyed participant perceptions and understanding of A5345 using a cross-sectional sociobehavioral questionnaire. Participants completed the baseline questionnaire either
-
HIV and SARS-CoV-2 Co-infection: A Systematic Review of the Literature and Challenges AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-02-18 Mr. Raj H Patel; Dr. Arpan Acharya; Dr. Hitendra S Chand; Dr. Mahesh Mohan; Dr. Siddappa N Byrareddy
Objectives The concurrence of infection with human immunodeficiency virus (HIV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, presents an intriguing problem with many uncertainties underlying their pathogenesis. Despite over a 96.2 million cases of COVID-19 worldwide as of January 22nd, 2021, reports of patients co-infected with HIV and SARS-CoV-2
-
Update in natural antiretroviral-associated mutations among HIV-2 variants and discrepancies across HIV-2 resistance interpretation tools AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-02-15 Dr. Paloma Troyano-Hernáez; Mr. Roberto Reinosa; Dr. María Concepción Burgos; Dr. África Holguín
HIV variants carry natural polymorphisms related to drug-resistance (R-markers) fixed during viral evolution in the absence of antiretroviral therapy (ART) that may impact on drug susceptibility and resistance pathways. We aimed to identify the HIV-2 variant-specific R-markers at Pol in all available sequences from ART-naïve subjects deposited in Los Alamos database according to reported HIV-2 drug
-
The 1G/1G + 1G/2G genotypes of MMP1 rs1799750 are associated with higher levels of MMP-1 and are both associated with lipodystrophy in people living with HIV on antiretroviral therapy? AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-02-15 Mrs. Andreia Soares da Silva; Dr. Maria do Socorro de Mendonça Cavalcanti; Dr. Taciana Furtado de Mendonça Belmont; Dr. Ricardo Arraes de Alencar Ximenes; Miss Aline Vieira da Silva; Miss Débora Nascimento da Nóbrega; Miss Roberta dos Santos Souza; Ms. Isabela Cristina Cordeiro Farias; Ms. Kleyton Palmeira do Ó; Dr. Luydson Richardson Silva Vasconcelos; Dr. George Tadeu Nunes Diniz; Dr. Demócrito de
In HIV-infected patients, antiretroviral therapy (ART) is associated to adipose tissue redistribution known as lipodystrophy (LD). This study aimed to verify the association between the polymorphism of the MMP1 gene (rs1799750) (1G/2G) and the serum levels of MMP-1 with LD and its subtypes in people living with HIV on ART. Analytical cross-sectional study. LD was self-reported. The determination of
-
Lamivudine plus dolutegravir improves bone mineral density compared to emtricitabine/tenofovir alafenamide plus an integrase inhibitor AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-02-15 Dr. Arturo Ciccullo; Dr. Gianmaria Baldin; Dr. Vanni Borghi; Dr. Anna Pia Lassandro; Dr. Damiano Farinacci; Dr. Giovanni Guaraldi; Cristina Mussini; Dr. Simona Di Giambenedetto
N/A
-
Efficacy and safety of dolutegravir plus lamivudine as a first-line regimen in clinical practice AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-02-15 Dr. Arturo Ciccullo; Dr. Gianmaria Baldin; Dr. Alex Dusina; Dr. Maria Vittoria Cossu; Dr. Francesca Lombardi; Dr. Alberto Borghetti; Dr. Amedeo Ferdinando Capetti; Dr. Simona Di Giambenedetto
Background. The GEMINI trials have showed that the two drugs regimen of dolutegravir+lamivudine was non-inferior to a 3-drug regimen as a first line regimen for treatment-naïve PLWHIV. Aim of our study was to confirm, in a real-life setting, the efficacy of this regimen. Materials and methods. We conducted a retrospective, observational study enrolling treatment-naïve patients starting a first-line
-
PRESSING QUESTIONS AND CHALLENGES IN THE HIV-1 AND SARS-COV-2 SYNDEMIC AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-02-15 Dr. Monty Montano
Since emerging into the human population in late 2019, the severe acute respiratory syndrome coronavirus -2 (SARS-CoV-2) has reached across the globe to infect over 80 million people. The coronavirus disease - 2019 (COVID-19) caused by SARS-CoV-2 can range in severity from mild and asymptomatic to severe and fatal. Identifying risk factors for adverse outcomes in COVID-19 is a major challenge. In the
-
The impact of the COVID-19 pandemic on people living with HIV in Victoria, Australia AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-02-15 Dr. Mihiri Weerasuria; Dr. Christy Ko; Mr. Adam Ehm; Ms. Jessica O'Bryan; Dr. James H McMahon; Prof. Ian Woolley; Dr. Jennifer Hoy; Dr. Jillian Lau
As of 12th January 2021, Australia has reported 28,634 COVID-19 cases. Most (20,411) cases are from the state of Victoria. In response to rising infections and community transmission in July 2020, on 2nd August several restrictions were imposed for the following 111 days, including an 8pm curfew, a travel restriction to 5km from home, and closure of non-essential services. It is unknown how this affected
-
Expression, activity, and regulation of phosphorylating enzymes in tissues and cells relevant to HIV-1 sexual transmission AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-02-10 Dr. Minlu Hu; Dr. Guru Raghavendra Valicherla; Dr. Tian Zhou; Dr. Sharon L. Hillier; Dr. Lisa Cencia Rohan
Phosphorylating enzymes (PEs) are responsible for activating nucleoside reverse transcriptase inhibitors (NRTIs) such as tenofovir (TFV) and are critical for their conversion to obtain intracellular antiviral activity. However, there are limited data available regarding the expression of PEs and their activity in the female genital tract. This work compared the mRNA expression levels of PEs in human
-
Antiretroviral Laboratory Monitoring and Implications for HIV Clinical Care in the Era of COVID-19 and Beyond AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-02-10 Dr. Lawrence York; Dr. Julia M Fisher; Ms. Lakshmeeramya Malladi; Dr. Jessica A August; Dr. Kristen E Ellis; Dr. Jose L Marquez; Ms. Ashwini Kaveti; Ms. Marine Khachatryan; Ms. Marissa K Paz; Dr. Matthew D Adams; Dr. Edward J Bedrick; Dr. Lori E Fantry
Background: In the era of COVID-19, providers are delaying laboratory testing in people with HIV (PWH). The purpose of this study was to examine the clinical significance of renal, liver, and lipid testing. Methods: We reviewed the charts of 261 PWH who initiated care at an academic HIV clinic between 1/1/16 and 12/21/18. Analysis included one-sided binomial exact tests and multiple linear, Poisson
-
The LAIs Are Coming! Implementation Science Considerations for Long-Acting Injectable Antiretroviral Therapy in the United States: A Scoping Review AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-02-05 John T. Kanazawa; Parya Saberi; John A. Sauceda; Karine Dubé
Long-acting injectable antiretroviral therapy (LAI-ART) is one of the latest advancements in HIV control with the potential to overcome oral ART barriers to adherence. The objective of this article is to anticipate and examine implementation considerations for LAI-ART using components of the PRISM model, a Practical, Robust Implementation and Sustainability Model for integrating research findings into
-
APOC3 Gene Polymorphism and Antiretroviral Therapy-Induced Dyslipidemia in HIV-Infected Children AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-02-05 Ramalingam Srinivasan; Chandrasekaran Padmapriyadarsini; Karunaianantham Ramesh; G.N. Sanjeeva; Devarajulu Reddy; Elumalai Suresh; Ramesh Kumar; Pattabiraman Sathyamoorthy; Soumya Swaminathan; Anita Shet
Children exposed to antiretroviral therapy (ART) are at risk of developing metabolic complications. The association between gene polymorphisms and the development of dyslipidemia in children post ART initiation was studied. Children initiating first-line ART were followed for 2 years at the National Institute for Research in Tuberculosis (Chennai, India), and St. John's Medical College Hospital (Bangalore
-
Prevalence of Silent Atherosclerosis and Other Comorbidities in an Outpatient Cohort of Adults Living with HIV: Associations with HIV Parameters and Biomarkers AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-02-05 Jade Ghosn; Hendy Abdoul; Soraya Fellahi; Audrey Merlet; Dominique Salmon; Jean-Pierre Morini; Jean Deleuze; Jacques Blacher; Jacqueline Capeau; Jean-Philippe Bastard; Jean-Paul Viard
People living with HIV (PLWH) are at risk of noninfectious comorbidities. It is important to individualize those at higher risk. In a single-center cohort of PLWH, we performed a cross-sectional analysis of comorbidities, diagnosed according to standard procedures. The primary endpoint was the prevalence of subclinical carotid/coronary atherosclerosis. Secondary endpoints were its association with
-
Micro RNA Targets in HIV Latency: Insights into Novel Layers of Latency Control AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-02-05 Ashley I. Heinson; Jeongmin Woo; Amey Mukim; Cory H. White; Bastiaan Moesker; Alberto Bosque; Celsa A. Spina; Christopher H. Woelk; Ben D. Macarthur; Nadejda Beliakova-Bethell
Despite the considerable progress that has been made in identifying cellular factors and pathways that contribute to establishment and maintenance of the latent HIV reservoir, it remains the major obstacle to eradicating this virus. Most recently, noncoding genes have been implicated in regulation of HIV expression. In this study, small RNA sequencing was used to profile expression of microRNAs (miRNAs)
-
Immune Markers and Their Association with Bone Density in Children, Adolescents, and Young Adults with Perinatally Acquired HIV AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-02-05 Denise Jacobson; Jeremiah Zhe Liu; Jane C. Lindsey; Stephanie Shiau; Brent Coull; Grace Aldrovandi
To describe distributions of immune markers in children and young adults by sex and HIV status, and within groups, investigate associations of immune markers with bone density across Tanner stage. Using data and samples from 353 participants in a cross-sectional study in youth with perinatally acquired HIV (PHIV) and matched HIV-negative controls, distributions of inflammation and activation immune
-
Drug Injection-Related Norms and High-Risk Behaviors of People Who Inject Drugs in Athens, Greece AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-02-05 Andria Hadjikou; Ioanna D. Pavlopoulou; Katerina Pantavou; Andrea Georgiou; Leslie D. Williams; Eirini Christaki; Konstantinos Voskarides; Giagkos Lavranos; Demetris Lamnisos; Enrique R. Pouget; Samuel R. Friedman; Georgios K. Nikolopoulos
Drug use involves social interactions. Therefore, norms in the proximal environment of people who inject drugs (PWID) can favor behaviors that may result in HIV transmission. This work aimed at studying drug injection-related norms and their potential association with risky behaviors among PWID in Athens, Greece, in the context of economic recession and political activism that followed the fiscal crisis
-
Intrapatient Evolutionary Dynamics in an Individual Infected with HIV-1 CRF01_AE Who Experienced Periods of Treatment Failure AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-02-05 Xiaorong Peng; Yufan Xu; Ying Huang; Biao Zhu
Although previous studies have analyzed cross-level CRF01_AE viral genomic data in populations, less is known about intrapatient viral evolutionary dynamics during antiretroviral therapy (ART) failure. We longitudinally sampled plasma and peripheral blood mononuclear cells (PBMC) at different time points from one human immunodeficiency virus type 1 infected patient. The evolution of viral quasispecies
-
The Genetic Diversity of HIV-1 Within Antiretroviral-Naive Outpatients in Ganzhou, China AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-02-05 Ying-Na Xie; Yu-Ning Zhang; Si-Wei Cheng; Dan-Dan Huang; Bing-Yu Xie; Zhen Huang; Yan-Heng Zhou; Da-Qing Zhu; Xin Chen
To explore the molecular epidemiological status of human immunodeficiency virus type 1 (HIV-1) in Ganzhou, China, eight HIV-1–positive outpatients were recruited from July 5 to 21, 2018. Six HIV-1 near-full-length sequences were amplified and sequenced from the plasma samples that were collected before the patients' antiretroviral treatments. Phylogenetic and bootscan analyses revealed that one of
-
Near Full-Length Genomic Characterization of a Novel HIV-1 Circulating Recombinant Form (CRF107_01B) Identified Among Men Who Have Sex with Men in Heilongjiang Province of China AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-02-05 Xiao Song; Jiajia Zhou; Miaomiao Li; Yi Feng; Hui Xing; Sun Wei
We reported a novel human immunodeficiency virus type 1 (HIV-1) circulating recombinant form (CRF) among four epidemiologically unlinked patients through men having sex with men in Heilongjiang Province, China. It was named CRF107_01B (this is temporary as we have not received the CRF number from HIV databases). A near full-length genome phylogenetic tree showed that CRF107_01B was generated by two
-
Genetic Characteristics of HIV-1 CRF12_BF First Identified in Guangdong Province, China AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-02-05 Yun Lan; Xiang He; Ruolei Xin; Linghua Li; Xuhe Huang; Xizi Deng; Xiaoping Tang; Weidong Jia; Weiping Cai; Fengyu Hu
Multiple HIV-1 genotypes were found circulating in Guangdong Province, China, as this province is located in South China and has a high frequency of international trade. In this study, we report the near full-length genome (NFLG) of CRF12_BF that was identified from a male patient in Guangzhou city, Guangdong Province; this is the first time CRF12_BF has been reported in mainland China. The NFLG was
-
Genetic Characterization of HIV-1 Subtype A1/C/D/B/K Unique Recombinant Form from Eastern Cape, South Africa AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-02-05 Oladele Vincent Adeniyi; Chikwelu Larry Obi; Daniel Ter Goon; Benson Iweriebor; Wezile Chitha; Anthony Okoh
HIV-1 subtype C is the predominant circulating virus in South Africa. There are reports of non-C subtypes emerging in different regions of the country, however, very little information exists on the genetic diversity of HIV in the Eastern Cape Province, despite having the third largest HIV epidemic in the country. In the current study, a near full-length genomic sequence obtained from a heterosexual
-
Sorting by Race/Ethnicity Across HIV Genetic Transmission Networks in Three Major Metropolitan Areas in the United States AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-02-08 Manon Ragonnet-Cronin; Nanette Benbow; Christina Hayford; Kathleen Poortinga; Fangchao Ma; Lisa A. Forgione; Zhijuan Sheng; Yunyin W. Hu; Lucia V. Torian; Joel O. Wertheim
An important component underlying the disparity in HIV risk between race/ethnic groups is the preferential transmission between individuals in the same group. We sought to quantify transmission between different race/ethnicity groups and measure racial assortativity in HIV transmission networks in major metropolitan areas in the United States. We reconstructed HIV molecular transmission networks from
-
Evidence of novel SARS-CoV-2 variants circulation in Romania AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-02-05 Mr. Marius Surleac; Ms. Corina Casangiu; Ms. Leontina Banica; Mr. Petre Milu; Mr. Dragos Florea; Mrs. Oana Sandulescu; Mrs. Anca Streinu-Cercel; Mr. Ovidiu Vlaicu; Ms. Andreea Tudor; Mr. Robert Hohan; Dr. Simona Paraschiv; Mr. Dan Otelea
New SARS-CoV-2 variants are constantly emerging and putting a strain on public health systems by spreading faster and potentially evading immune protection through vaccination. One of these strains is the B.1.1.7 variant that has initially been described in the UK and has subsequently spread to several countries. Monitoring the amplification of the S gene – a major hotspot for molecular evolution –
-
Pretreatment HIV Drug Resistance Among Adults Initiating or Re-Initiating First-Line Antiretroviral Therapy in Zimbabwe: Fast-Tracking the Transition to Dolutegravir-Based First-Line Regimens? AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-02-05 Vinie Kouamou; Justice Mavetera; Justen Manasa; Chiratidzo Ellen Ndhlovu; David Katzenstein; Alan Michael McGregor
Pretreatment drug resistance (PDR) can compromise antiretroviral therapy (ART) efficacy and undermine the WHO targets to end the AIDS epidemic as a public health threat by 2030. Thus, we examined the level of PDR in Harare, Zimbabwe. Eligible study participants were adults who were ART naive or individuals with previous ART exposure reinitiating treatment, recruited between October 2018 and February
-
High Prevalence of Frailty and Prefrailty Status in Brazilian Patients Living with HIV AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-02-04 Iris Montaño-Castellón; Diana Zeballos; Gabriel Gutiérrez-Peredo; Eduardo Netto; Carlos Brites
Frailty is associated with an increased probability of serious adverse health outcomes in the geriatric general population. People living with HIV have a higher prevalence of frailty. However, the magnitude of this problem in younger patients in South America is unknown. We aimed to determine the prevalence and factors associated with frailty. This is a cross-sectional study from the Brazilian cohort
-
Antiretroviral Therapy for HIV-Associated Cutaneous Kaposi's Sarcoma: Clinical, HIV-Related, and Sociodemographic Predictors of Outcome AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-02-02 Owen Ngalamika; Sody Munsaka; Salum J. Lidenge; John T. West; Charles Wood
Kaposi's sarcoma (KS) is an AIDS-defining malignancy that can improve or worsen with antiretroviral therapy (ART). We aimed at identifying clinical, HIV-related, and sociodemographic factors associated with either progression or nonprogression (regression or stable disease) of ART-treated HIV-associated KS in patients with limited cutaneous disease. We conducted a prospective cohort study of ART-treated
-
Phylogenetic Analysis of Sequences in the HIV Database Revealed Multiple Potential Circulating Recombinant Forms in China AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-02-01 Xiaorui Wang; Yu Zhang; Yongjian Liu; Hanping Li; Lei Jia; Jingwan Han; Tianyi Li; Xiaolin Wang; Jingyun Li; Hongling Wen; Lin Li
HIV recombination contributes greatly to its diversity and produces many circulating recombinant forms (CRFs) and unique recombinant forms (URFs). In China, 24 CRFs have been reported to date, and CRFs cause more than 80% of HIV infections. However, the prevalence of CRFs might still be underestimated, as a high level of onward transmission of URFs has been reported. In this study, we analyzed all
-
Safety, Immune, and Antiviral Effects of Pegylated Interferon Alpha 2b Administration in Antiretroviral Therapy-Suppressed Individuals: Results of Pilot Clinical Trial AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-01-29 Emmanouil Papasavvas; Livio Azzoni; Amélie Pagliuzza; Mohamed Abdel-Mohsen; Brian N. Ross; Matthew Fair; Bonnie J. Howell; Daria J. Hazuda; Nicolas Chomont; Qingsheng Li; Karam Mounzer; Jay R. Kostman; Pablo Tebas; Luis J. Montaner
In the pilot NCT01935089 trial, we tested whether pegylated interferon alpha2b (Peg-IFN-α2b) with antiretroviral therapy (ART) was safe and could impact HIV and immune measures in blood and in gut-associated lymphoid tissue (GALT). Twenty HIV-1+ ART-suppressed individuals received 1 μg/kg/week Peg-IFN-α2b with ART for 20 weeks, with intermediate 4-week analytical ART interruption (ATI). Safety, immune
-
Validation of the Asante™ HIV-1 Rapid Recency® Assay for detection of recent HIV-1 infections in Uganda AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-01-27 Dr. Ronald Moses Galiwango; Mr. Charles Ssuuna; Prof. Pontiano Kaleebu; Dr. Godfrey Kigozi; Joseph Kagaayi; Dr. Gertrude Nakigozi; Dr. Steven James Reynolds; Mr. Tom Lutalo; Dr. Edward Nelson Kankaka; Mr. John Bosco Wasswa; Ms. Sarah N Kalibbala; Mrs. Aminah N Kigozi; Dr. Christine Watera; Ms. Julia Ejang; Mr. Anthony Ndyanabo; Mr. Aggrey J Anok; Dr. Deogratius Ssemwanga; Dr. Freddie M Kibengo; Dr
Objective: Point of care rapid recency testing for HIV-1 may be a cost-effective tool to identify recently infected individuals for incidence estimation, and focused HIV prevention through intensified contact tracing. We validated the Asante™ HIV-1 rapid recency® assay for use in Uganda. Methods: Archived specimens (serum/plasma), collected from longitudinally observed HIV-1 recently and long-term
-
Human Immunodeficiency Virus (HIV) and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: A Meta-Analysis and Meta-Regression AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-01-27 Dr. Timotius Ivan Hariyanto; Dr. Cynthia Putri; Dr. Pricilla Frinka; Dr. Jessica Louisa; Dr. Nata Pratama Hardjo Lugito; Dr. Andree Kurniawan
Background: The number of positive and death cases from coronavirus disease 2019 (COVID-19) is still increasing until now. One of the most prone individuals, even in normal situations is patients with HIV. Currently, the evidence regarding the link between HIV and COVID-19 is still limited and conflicting. This study aims to analyze the relationship between HIV and poor outcomes of COVID-19 infection
-
What Are the Risk Factors for Surgical Site Infection in HIV-Positive Patients Receiving Open Reduction and Internal Fixation of Traumatic Limb Fractures? A Retrospective Cohort Study AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-01-27 Rugang Zhao; Rui Ding; Qiang Zhang
A lack of studies analyze risk factors associated with surgical site infection (SSI) in human immunodeficiency virus (HIV)-positive patients with trauma undergoing orthopedic surgery. We questioned, (1) “What is the proportion of SSI in HIV-positive patients receiving open reduction and internal fixation (ORIF) of traumatic limb fractures?” and (2) ”What are the independent risk factors for SSI of
-
Pro-Inflammatory Interleukin-18 is Associated with Hepatic Steatosis and Elevated Liver Enzymes in People with HIV Monoinfection AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-01-25 Jae H. Sim; Julia B. Sherman; Takara L. Stanley; Kathleen E. Corey; Kathleen V. Fitch; Sara E. Looby; Jake A. Robinson; Michael T. Lu; Tricia H. Burdo; Janet Lo
People with HIV (PWH) are at an increased risk of developing nonalcoholic fatty liver disease (NAFLD). Interleukin (IL)-18 is regulated by inflammasomes in response to pathogens and danger signals and has been implicated in both the pathogenesis of NAFLD and HIV disease progression. We hypothesized that increased IL-18 may be associated with NAFLD and liver injury in PWH. This was an observational
-
Examining the Safety, Pharmacokinetics, and Pharmacodynamics of a Rectally Administered IQP-0528 Gel for HIV Pre-Exposure Prophylaxis: A First-In-Human Study AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-01-25 Amer Al-Khouja; Eugenie Shieh; Edward J. Fuchs; Mark A. Marzinke; Rahul P. Bakshi; Pamela Hummert; Anthony S. Ham; Karen W. Buckheit; Jennifer Breakey; Ethel D. Weld; Huan Chen; Brian S. Caffo; Robert W. Buckheit; Craig W. Hendrix
A lubricating microbicide gel designed for rectal and vaginal use would provide a behaviorally congruent strategy to enhance pre-exposure prophylaxis adherence and reduce HIV infection risk. In this study, we report the first-in-human evaluation of such a gel containing 1% IQP-0528, an investigational antiretroviral. Seven HIV-1-negative participants received one 10 mL rectal dose of radiolabeled 1%
-
Near Full-Length Genomic Characterization of 16 HIV-1 CRF01_AE Primary Isolates from Guangxi, China AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-01-25 Guoxin Zhu; Jingwan Han; Hanping Li; Yongjian Liu; Lei Jia; Tianyi Li; Xiaolin Wang; Jingyun Li; Shenghai Huang; Lin Li
Isolation and culture of human immunodeficiency virus (HIV) are an important basis for acquired immune deficiency syndrome (AIDS) etiology, immunology, drug screening, clinical treatment, and vaccine research. CRF01_AE is one of the predominant strains of HIV-1 in China. However, there are few HIV-1 CRF01_AE isolates that have been reported. In this study, 16 HIV-1 CRF01_AE strains from Guangxi, China
-
Dolutegravir-based regimen for maintenance of viral suppression in people living with HIV: 48‐week results in real life setting. AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-01-24 Dr. Daniele Di Carlo; Dr. Francesca Falasca; Dr. Enrico Palermo; Dr. Ivano Mezzaroma; Dr. Caterina Fimiani; Dr. Guido Siccardi; Dr. Luigi Celani; Dr. Francesco Maria Di Campli; Dr. Gabriella d'Ettorre; Prof. Guido Antonelli; Prof. Ombretta Turriziani
To evaluate the efficacy, safety and tolerability of switching to a dolutegravir (DTG)-based regimen in a cohort of virological suppressed HIV-infected patients. The dynamics of total HIV-DNA and levels of high-sensitivity c-reactive protein (hsCRP), interleukin-6 (IL-6), soluble-CD14 (sCD14) and D-Dimer were also analyzed. Ninety-six individuals who switched to a DTG-containing regimen were followed
-
Risk of Tumor Onset in HIV+ Patients on Two-Drug Regimens: A Cohort Study in an Italian Hospital AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-01-21 Alberto Borghetti; Stefania Bellino; Francesca Lombardi; Matteo Whalen; Simone Belmonti; Davide Moschese; Arturo Ciccullo; Enrica Tamburrini; Gianmaria Baldin; Alex Dusina; Elena Visconti; Arianna Emiliozzi; Silvia Lamonica; Patrizio Pezzotti; Simona Di Giambenedetto
Currently approved 2-drug therapies are as effective as 3-drug regimens but could potentially lead to increased cancer risk due to less efficient immune recovery. We conducted a longitudinal cohort study in a tertiary Italian hospital to investigate HIV+ patients starting a triple therapy (TT) (2 NRTIs +3rd agent) or a dual therapy (DT) (3TC/FTC+boosted-PI, boosted-DRV+RAL, and 3TC/FTC or RPV+DTG)
-
Feasibility of Implementing Long-Acting Injectable Antiretroviral Therapy to Treat HIV: A Survey of Health Providers from the 13 Countries Participating in the ATLAS-2M Trial AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-01-19 Deanna Kerrigan; Miranda Murray; Tahilin Sanchez Karver; Andrea Mantsios; Nicki Walters; Krischan Hudson; Emma Kaplan-Lewis; Federico Pulido; Ayesha Cassim Bassa; David Margolis; Noya Galai
Long-acting (LA) injectable antiretroviral therapy (ART) was found noninferior to daily oral ART in Phase 3 trials with high patient satisfaction. Limited information on provider experiences with LA ART exists, which is critical to inform real-world implementation. An online survey of health providers from the 13 countries participating in the Phase 3b ATLAS-2M trial was conducted. A total of 293 providers
-
Genetic Characteristics of Three Unique Recombinant Forms of HIV-1 in Yunnan, China AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-01-18 Ying-Na Xie; Si-Le Li; Rong-Rong Yang; Jin Huang; Xia Peng; Wen Xu; Si-Wei Cheng; Yan-Heng Zhou; Xin Chen; Hong Li
To explore the molecular epidemiological status of human immunodeficiency virus type 1 (HIV-1) in Yunnan, China, three HIV-1 near full-length genomes were amplified and sequenced from plasma samples that were collected from Burmese patients newly diagnosed with HIV-1 in Dehong Prefecture in Yunnan Province in 2017. Phylogenetic and bootscanning analyses revealed that all the sequences might be HIV-1
-
SIV susceptibility, immunology and microbiome in the female genital tract of adolescent versus adult pigtail macaques AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-01-15 Dr. Alicia R Berard; Ms. Charlene Miller; Dr. Mariluz Araínga; Ms. Courtney Ann Broedlow; Mrs. Laura Noël-Romas; Dr. Luca Schifanella; Dr. Tiffany Hensley-McBain; Mr. Alex Roederer; Mr. Connor Driscoll; Mr. Ernesto Coronado; Dr. Jennifer Manuzak; Dr. Lyle R McKinnon; Dr. Francois J Villinger; Dr. Thomas J Hope; Dr. Adam D Burgener; Dr. Nichole R Klatt
In Sub-Saharan Africa, young women aged 15-24 account for nearly 30% of all new HIV infections, however biological and epidemiological factors underlying this disproportionate infection rate are unclear. Here, we assessed biological contributors of SIV/HIV susceptibility in the female genital tract (FGT) using adolescent (n=9) and adult (n=10) pigtail macaques (PTMs) with weekly low-dose intravaginal
-
Metabolism of Long-Acting Rilpivirine After Intramuscular Injection: HIV Prevention Trials Network Study 076 (HPTN 076) AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-01-13 Herana Kamal Seneviratne; Joseph Tillotson; Julie M. Lade; Linda-Gail Bekker; Sue Li; Subash Pathak; Jessica Justman; Nyaradzo Mgodi; Shobha Swaminathan; Nirupama Sista; Jennifer Farrior; Paul Richardson; Craig W. Hendrix; Namandje N. Bumpus
A long-acting injectable formulation of rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor, is currently under investigation for use in human immunodeficiency virus (HIV) maintenance therapy. We previously characterized RPV metabolism after oral dosing and identified seven metabolites: four metabolites resulting from mono- or dioxygenation of the 2,6-dimethylphenyl ring itself or either
-
Acquisition of Additional Nuclear Factor Kappa B Binding Sites in Long Terminal Repeat of Genetically Evolving HIV-1 Subtype C Viral Species in Host with Comorbidities AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-01-13 Gurleen; Aman Sharma; Sunil K. Arora
HIV-1 causes millions of deaths around the world. Higher disease progression and mortality are seen in HIV positive individuals with comorbidities. Two of the most pertinent conditions are coinfection with Mycobacterium tuberculosis and Intravenous Drug abuse. The mechanisms involved, however, still remain unresolved. To elucidate the mechanisms involved, we evaluated the genetic alterations in terms
-
Characterization of HIV-1 Envelope V3 Region Sequences from Virologically Controlled HIV-Infected Older Patients on Long Term Antiretroviral Therapy AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-01-12 Nicole E. Behrens; Maria Love; Meghana Bandlamuri; Dana Bernhardt; Anne Wertheimer; Stephen A. Klotz; Nafees Ahmad
Although many HIV-infected patients have attained older age owing to the success of antiretroviral therapy (ART) in controlling viremia and increasing CD4 T cell counts, HIV continues to persist in several target cells. We have characterized 514 HIV-1 envelope V3 region sequences (94–96 amino acids [aa]) from 25 HIV-infected older patients' peripheral blood mononuclear cell DNA on long-term ART with
-
First Assessment of Acquired HIV-1 Drug Resistance and Mutation Patterns in Suriname AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-01-12 Rachel Sno; Mergiory Y. Labadie-Bracho; Meritha G. Grünberg; Malti R. Adhin
HIV drug resistance testing is fundamental in clinical patient management, but data on HIV-1 drug-resistant mutations (DRMs) is scarce in the Caribbean and in Suriname limited to one survey on transmitted resistance. The aim of this study was to address this gap, to gain insight in acquired HIV drug resistance (ADR) prevalence and mutation patterns, and to improve HIV-1 treatment outcome of people
-
Weight and Body Mass Index Change After Switching to Integrase Inhibitors or Tenofovir Alafenamide Among Women Living with HIV AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-01-12 Cecile D. Lahiri; Yanxun Xu; Kunbo Wang; Jessica A. Alvarez; Anandi N. Sheth; Jane O'Halloran; Amanda B. Spence; Phyllis Tien; Deborah R. Gustafson; Joel Milam; Margaret A. Fischl; Deborah Konkle-Parker; Adaora A. Adimora; Anjali Sharma; Kathleen M. Weber; Igho Ofotokun; Leah H. Rubin
Weight and body mass index (BMI) change was assessed among women after switch to integrase inhibitors (INSTIs) and/or tenofovir alafenamide (TAF). From 2006 to 2019, 1,458 women living with HIV enrolled in the Women's Interagency HIV Study and on antiretroviral therapy (ART) with ≥1 study visit before and after switching to INSTIs and/or TAF were included. Weight and BMI were compared pre- and postswitch
-
Near Full-Length Genomic Characterization of a Novel HIV-1 B/C Recombinant Form Identified in Guangdong Province, China AIDS Res. Hum. Retrovir. (IF 1.765) Pub Date : 2021-01-12 Yun Lan; Linghua Li; Xizi Deng; Xiaoli Cai; Junbin Li; Qinghong Fan; Liya Li; Weiping Cai; Chunliang Lei; Fengyu Hu
The wide variety of new HIV-1 recombinant variants are a predominant challenge for understanding the molecular epidemiology and preventing the spread of the HIV-1 epidemic. In this study, we confirmed a novel HIV-1 unique B/C recombinant (ZLQ01186) isolated from a male patient infected with HIV-1 through injection drug use in Foshan city, Guangdong Province. The near full-length genome was amplified